The Comité d’orientation stratégique et scientifique de la filière (COSSF) is the scientific advisory board of MabDesign.
It has 16 permanent experts.
- Thierry Wurch
EVOTEC
SVP Integrated Biologics Discovery, EVOTEC
- Brian Mullan
YPOSKESI
Head, Process and Analytical Development, Cell and Gene Therapies at Yposkesi
read more
Alain Beck
Pierre Fabre
Senior Director, Biologics CMC & developability of the CIPF, associated editor of mAbs Journal
Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs (2009) and chairman of MabDesign SAB (2014). He is or was involved in +10 clinical stage biologics R&D programs including dalotuzumab (Merck), telisotuzumab/ telisotuzumab vedotin (AbbVie), lonigutamab ugodotin ADC and W0180 Vista mAb (PF), ER004 Fc-fusion protein (www.esperare.org) and VB421/ lonigutamab (www.valenzabiotech.com). He is author/ co-author of +250 publications (h-index: 60; +14,000 citations). He has contributed to +280 scientific meetings (AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chairman, invited speaker, panellist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013) and was the 6th WADC (2019) and the 10th AIS Award winner (2022) for long and outstanding contribution in the fields. He is member of the MAB Working Party (EDQM/PhEur) and involved in workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.
Paul Baduel
Sanofi
Director Manufacturing Technology International Sites, Sanofi-Pasteur
Paul has graduated in biochemical engineering from National Institute of Applied Sciences (Toulouse France) in 1986. He started his carrier in 1988 as Research Scientist in molecular biology at Rhône-Poulenc Santé in charge of development of processes for production of recombinant proteins.
In the 90’s he was in charge of process development for new antibiotics and contributed to the industrialisation of recombinant process for Vitamin B12. Then he was appointed Project Manager for the development of new semi-synthetic anti-infective. Then Paul was appointed Manager of the Biotechnology department at Rhône-Poulenc Rorer for late stage development compounds and support to commercial products.
From 2000 to 2012 Paul was leading the Process Development Biotechnology Department of Aventis in France, Germany and Italy. In this Position Paul was in charge of support to industrial production and development of recombinant proteins (Insulin), Monoclonal Antibodies, antibiotics, Vitamin and Steroids.
Since 2013, Paul was responsible for Global Technology Innovation within Sanofi-Pasteur, the Vaccine division of Sanofi. He is today Director Manufacturing Technology International Sites for Sanofi Pasteur Industrial Operations.
Pierre-Louis Hervé
DBV Technologies
Director Research & Innovation at DBV Technologies
Pierre-Louis Hervé is a Virologist by training and performed his PhD at the Pasteur Institute of Paris. Here, he worked at developing new vaccinal approaches against highly pathogenic influenza viruses and at better understanding the molecular mechanisms of viral escape from vaccine-induced immune responses. Then, Pierre-Louis joined the INRAE at Jouy-en-Josas where he developed novel nanoparticle vaccines against respiratory viruses. Pierre-Louis joined DBV Technologies in 2015 as a Researcher in the Research & Innovation department. Here, he focused on new proof of concept aiming to demonstrate the feasibility and the efficacy of vaccines administered via the epicutaneous route. Since 2020, Pierre-Louis is responsible for defining DBV’s scientific strategy in a way to extend its pipeline.
Jean-Louis Pinquier
MEDICEN
MD, Chairman of the Translational Medicine committee at MEDICEN, and consultant at DECISIONS R&D Consulting.
Jean-Louis Pinquier is a medical doctor, currently Chairman of the Translational Medicine committee at MEDICEN, and consultant at DECISIONS R&D Consulting. Over these past 30 years he has been involved in more than hundred drug development programs from discovery to registration and beyond. He was particularly active in early clinical development, covering multiple therapeutics areas. Since the early 2000s, he was involved in several biologics program including naked and drug conjugate monoclonal antibodies. Up to 2014 he was deputy global head of the Clinical and Exploratory Pharmacology Dept. at Sanofi R&D, and member of Sanofi R&D France Board. After having spent 7 years in Cochin University Hospital as assistant professor and medical director of the Therapeutics Research Institute, he moved to pharmaceutical industry in 1993, first at Synthelabo Research, Sanofi-Synthelabo, and then Aventis and Sanofi-Aventis.
Dr Pinquier is board certified in Clinical Pharmacology, Internal Medicine and Rheumatology and still has clinical practice. He is member of ASCPT, ACCP, SFTP, Club Phase I (actual president) and EUFEMED.
Jean-François Prost
GamaMabs Pharma
Vice-President R&D and Strategy at GamaMabs Pharma
Jean-François is a Senior Executive of the French and International pharmaceutical industry. Physician specialist in Internal Medicine, Dr. Prost has an experience of 30 years in the industry, having served as Cardiovascular Development Director then Research Director at Servier, R&D Director at Pierre Fabre Medicament and then UCB Pharma, and finally in the last ten years, Scientific and Medical Management at LFB. He’s today VP R&D and Strategy at GamaMabs Pharma company.
Jérôme Tiollier
Our Future Universe
Chairman, Co-founder, Our Future Universe
Jérôme TIOLLIER PhD, 60 years old, has been working since 35 years in pharmaceutical R&D with experience in senior leadership positions (ExCom), in ww pharma & biotech. Over-sight & management of multiple areas of drug development, including CMC, toxicology, PK, non-clinical, translational scientific research, clin-reg operations up to early (Phase I/II) clinical phases. Set overall department and project goals, timelines, resource and budgets, resulting in meeting corporate goals in a fast-paced environment. Responsible for strategy and implementation, ultimately accountable for the quality of the work and its interpretation. Initial background in cellular biology and preclinical & clinical development of “first in class” products in different medical and therapeutic field.
Latest position within INNATE PHARMA as EVP Chief Development Officer (2001-2018), member of the IPH ExCom, he participates to build the strategy and corporate achievement. In 2008, he started the US operations as President IPH Inc. and other corporate business development activities. Previously, he has been with IMEDEX (1986-1997) a French biotech spin off from Institut Mérieux where he managed different biological products from preclinical to early clinical stage (phase I/II) with the collaboration of internal R&D groups and CRO. Then he moves to Pasteur-Mérieux Transplant business unit (acquired by SANGSTAT in 1998, now part of Sanofi Genzyme,) as Preclinical Director (1997-1999) and European R&D Director (1999-2001). In the positions, he managed different pharmaceutical product license building as well as global research projects. Graduated PhD with scientific background in cell biology and immunology.
In 2019 Jerome Tiollier starts with other seasoned managers of the industry a new venture of scientific media information website “sole in class” in the field: Our Future Universe (OFU).
Bernard Vanhove
Egle Therapeutics
Chief Operating Officer
Bernard Vanhove obtained his PhD from the University of Louvain (Belgium) and conducted an international academic and private career initiated at the Sandoz Vienna International Research Cooperation Centre (Austria) and at IMTIX-Sangstat (Lyon, France). He joined the CNRS (Centre National de Recherche Scientifique) in 1998 and became Research Director, working at the CRTI (Centre for Research in Transplantation and Immunology, Nantes, France). In 2013, Bernard Vanhove was awarded the « France Transplant » Prize for his work on the development of the first anti-CD28 antagonist antibody. He has been the coordinator of the European FP7 network « TRIAD » (Tolerance Restoration in Autoimmune Diseases) in autoimmune diseases. He authored > 120 international publications in the area of immuno-transplantation.
In 2008, Bernard Vanhove co-founded Effimune, becoming Chief Executive Officer, then Chief Operating Officer of OSE Immunotherapeutics until 2019, then Chief Scientific Officer of Xenothera (Nantes, France) and joined Egle Therapeutics (Paris) in 2022 as Chief Development Officer
Hervé Watier
MAbImprove
Professor of Immunology at the Faculty of Medicine, Tours
Head of the Laboratory of Immunology in the University Hospital of Tours.
Hervé Watier is Professor of Immunology at the Faculty of Medicine, Tours, and Head of the Laboratory of Immunology in the University Hospital of Tours. Physician (MD) and scientist (PhD), he is working on the mechanisms of action of therapeutic antibodies in humans, which he contributed to discover through pharmacogenetic approaches. Since 2009, he is Director of the CNRS Research Network “Antibodies and therapeutic targeting”. He is also coordinating the laboratory of excellence (LabEx) “MAbImprove” since 2011 and a regional program dedicated to “Biopharmaceuticals” since 2013.
Nicolas Poirier
OSE Immunotherapeutics
Chief Executive Officer & Chief Scientific Officer
Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, as project manager and then he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.
Stéphanie Cornen
Innate Pharma
Director, Research and development
Stéphanie Cornen joined Innate Pharma in May 2012 as R&D scientist in the Antibody Department. She became project manager in 2014 to work on the discovery of new first-in-class blocking antibodies. Since 2016, she leads the new target discovery program that aims to identify and validate new therapeutic targets in immuno-oncology. Stéphanie holds a PharmD and PhD in oncology (from Aix-Marseille University).
Brian Mullan
Yposkesi
Head, Process and Analytical Development, Cell and Gene Therapies at Yposkesi
Brian Mullan is a Biochemist and Virologist by training. He started his career in 2002 as a Marie Curie Industry Host Fellow at Aventis Pharma (now Sanofi), Vitry-sur-Seine, in Functional Genomics, working on adenoviral vector and AAV technologies (vector design and production platforms for R&D applications).
From 2006 to 2020, he worked in the area of manufacturing process development, launch and commercial supply for biologics (monoclonal antibodies) for Centocor (Janssen) Biologics, Eli Lilly and Novartis, as a Process Development Scientist, Tech Transfer Lead and Global CMC Product Lead. His last role was as Head, Manufacturing Science and Technology for the Novartis Huningue, FR, manufacturing site, where he oversaw numerous process improvement (stabilisations, yield increases), capacity management/process transfer projects, and implemented a Data & Insights approach for continuous improvement in process understanding and performance, leading to significant increases in yields and process efficiencies.
In October 2020, he joined Yposkesi, Paris Region, FR, as Head of Innovation, Analytical and Process Development. Yposkesi is a Contract Development and Manufacturing Organisation focused on the development and production of gene therapy vectors (AAV, Lentivirus) for human use. His role covers all analytical and process development activities, process industrialisation and technological innovation.
Sophie Derenne
French Blood Establishment
Head of the Department Analysis and Market Development at EFS
Pharmacist (PharmD) and scientist in Life science (PhD), Sophie DERENNE began her career in biological hematology at Nantes University Hospital and then joined the French Blood Establishment in 2005, notably as head of the Cell Therapy Unit from 2009.
From the opening of the EFS Atlantic Bio GMP in 2010, she was involved in the Production of Advanced Therapy Medicinal Products (ATMP) in cell and gene therapy, successively as Quality Manager, Qualified Person of the EFS pharmaceutical establishment and finally, head of the ATMP platform. During these years, she managed the regulatory and pharmaceutical aspects associated with ATMPs and was particularly involved in the development of ATMPs projects, in close collaboration with project leaders, to facilitate access to clinical trials.
Involved from October 2019 at the headquarters of the French Blood Establishment in a Cell Therapy and ATMPs mission, she joined the Department of Biology, Therapies and Diagnosis in March 2021 as Head of the Department Analysis and Market Development.
Félix A. Montero Julian
BioMérieux
Scientific Director, Healthcare Business, Industry Unit at BioMérieux
Félix Montero-Julian is the Scientific Director for the Healthcare Business of bioMérieux (Lyon, France). Felix has over 25 years of experience in industrial and clinical diagnostics, and previously served as the Chemunex Ivry-sur-Seine site & R&D Director in bioMérieux.
Felix is a member of different scientific organizations, such as the Parenteral Drug Association (MD, USA), and served as an expert in a panel for the Development of Compendial Rapid Sterility Tests for the US Pharmacopeia (MD, USA). Félix has been, and continues to be, extensively involved in the implementation and acceptance of rapid and alternative microbiological methods.
He is a prominent speaker at congresses and conferences and a regular contributor to bioMérieux scientific white papers. Félix has extensive technical experience that includes the development of in vitro diagnostic and research use reagents and applications, cell and tissue culture systems, alternative and rapid microbiological methods, sterility testing, Mycoplasma detection, compendia methods, and cell and gene therapy processes.
Gregory Batt
INRIA / Institut Pasteur
Senior researcher, Head of InBio research group
Dr Batt studied molecular and cellular biology and computer science at the Ecole Normale Supérieure de Lyon. He received his PhD in computer science from the University of Grenoble in 2006. Prior to joining Inria in 2007, he was a postdoctoral researcher at Boston University. Since 2017, he leads the InBio team, an Inria/Institut Pasteur research group.
The InBio team is interested in understanding, controlling and optimizing cellular processes from the single cell to the cell population levels.
InBio members combine wet and dry biology in the same lab. They employ systems and synthetic biology approaches with control and active learning methods, together with stochastic and statistical modeling frameworks.
They also develop affordable bioreactor-based platforms with automated measurements and reactive experiment control.
In recent applications, they have designed an artificial differentiation system in yeast and used it to create consortia with tuneable composition, and have characterized protein secretion under various stress conditions to optimize production in yeast.
The COSSF’s mission is to contribute to the strategic scientific plans of action of MabDesign in the sector in order to foster innovation and economic development of companies as well as draft prospective reports on specific areas of the sector twice per year.